Live Breaking News & Updates on University Of South Florida Research Foundation Inc

Stay updated with breaking news from University of south florida research foundation inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million

Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , University Of South Florida Research Foundation Inc , Exchange Commission , Alzamend Neuro Inc , Securities Exchange , Alzamend Neuro , Securities Purchase Agreement , Convertible Preferred Stock , Preferred Shares , Each Preferred Share , Common Stock , Floor Price , Conversion Price , Current Report , United States Securities , Securities Act , Investor Relations , South Florida Research Foundation , Securities Exchange Act ,

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , Ascendiant Capital Markets , Securities Exchange , University Of South Florida Research Foundation Inc , Exchange Commission , Alzamend Neuro Inc , Alzamend Neuro , Investor Relations , South Florida Research Foundation , Securities Act , Securities Exchange Act ,

Alzamend Neuro Receives FDA "Study May Proceed" Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients | Region

ATLANTA (BUSINESS WIRE) Dec 11, 2023 ....

United States , Stephan Jackman , Securities Exchange , Alzamend Neuro Inc , Exchange Commission , American Psychiatric Association , Drug Administration , University Of South Florida Research Foundation Inc , Chief Executive Officer , Study May Proceed , New Drug Application , Mayo Clinic , South Florida Research Foundation , Securities Act , Securities Exchange Act , Alzamend Neuro , Business Wire ,

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement -November 16, 2023 at 08:01 am EST

Alzamend Neuro, Inc. , an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease , bipolar disorder , major depressive. ....

United States , University Of South Florida Research Foundation Inc , Alzamend Neuro Inc , Exchange Commission , Securities Exchange , Alzamend Neuro , Listing Qualifications Staff , Nasdaq Stock Market , Nasdaq Listing Rule , Bid Price , Minimum Bid Price Requirement , Compliance Notice , Market Value , Listed Securities , Nasdaq Capital Market , South Florida Research Foundation , Securities Act , Securities Exchange Act ,

Alzamend Neuro, Inc. (ALZN) Stock Price | Stock Quote Nasdaq

Alzamend Neuro, Inc. (ALZN.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Alzamend Neuro, Inc. | Nasdaq: ALZN | Nasdaq ....

United States , University Of South Florida Research Foundation Inc , Alzamend Neuro Inc , Alzamend Neuro , South Florida Research Foundation , Nc Quotes , Tock Quote ,